331282-03-2

Upstream product

• 91307-39-0 ethyl 1,2,3,4-tetrahydro-4-hydroxy-2-naphthoate 
• 331282-01-0 benzyl 1-hydroxy-2,4-dichloro-5,6,7,8-tetrahydro-3-naphthylcarboxylate 
• 331282-02-1 benzyl 5,6,7,8-tetrahydro-1-hydroxy-3-naphthylcarboxylate 
• 220151-26-8 ethyl 1-hydroxy-5,6,7,8-tetrahydro-3-naphthylcarboxylate 
• 91586-32-2 5,6,7,8-tetrahydro-1-hydroxy-3-naphthoic acid 
• 66979-47-3 ethyl 2-oxo-5,6,7,8-tetrahydro-2H-1-benzopyran-3-carboxylate 

Downstream Products

• 331282-31-6 1,3-dichloro-4-[2-(8-oxo-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid benzyl ester 
• 331282-09-8 1,3-dichloro-4-[2-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

AMP deaminase inhibitors. 5. Design, synthesis, and SAR of a highly potent inhibitor series

A highly potent AMP deaminase (AMPDA) inhibitor series was discovered by replacing the N3 substitutents of the two lead AMPDA inhibitor series with a conformationally restricted group. The most potent compound, 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydrona